HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells

Cancer Research

Volumn 64, Issue 14, 2004, Pages 4980-4986

  Liu, Gentao ^a   Ying, Han ^a   Zeng, Gang ^b   Wheeler, Christopher J ^a   Black, Keith L ^a   Yu, John S ^a,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA A1 ANTIGEN; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 1; MESSENGER RNA; PEPTIDE FRAGMENT; TETRAMER;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LYMPHOCYTE CLONE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL; UPREGULATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; AZACITIDINE; BRAIN NEOPLASMS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DNA METHYLATION; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INTERFERON TYPE II; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC;

EID: 3142710121     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3504     Document Type: Article

References (46)

1. Black KL, Pikul BK. Gliomas: past, present, and future. Clin Neurosurg 1999;45:160-3.
2. Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 1998;40:151-60.
3. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-80.
4. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Wash DC) 1991;254:1643-7.
5. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-7.
6. Inoue H, Mori M, Li J, et al. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer 1995;63:523-6.
7. Gotoh K, Yatabe Y, Sugiura T, et al. Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer 1998;20:117-25.
8. Chen CH, Huang GT, Lee HS, et al. High frequency of expression of MAGE genes in human hepatocellular carcinoma. Liver 1999;19:110-4.
9. Yamanaka K, Miyake H, Hala I, et al. Expression of MAGE genes in renal cell carcinoma. Int J Mol Med 1998;2:57-60.
10. Renkvist N, Castelli C, Robbins PF. A list of human tumor antigens recognized by T cells. http://www.cancerimmunity.org/statics/database.htm, 2003.
11. Riker AI, Kammula US, Panelli MC, et al. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int J Cancer 2000;86:818-26.
12. Lee RS, Tartour E, van der Bruggen P, et al. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur J Immunol 1998;28:2726-37.
13. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
14. Okamoto T, Irie RF, Fujii S, et al. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Investig Dermatol 1998;111:1034-9.
15. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
16. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (Wash DC) 2002;298:850-4.
17. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Wash DC) 1985;230:1132-9.
18. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash DC) 1989;244:707-12.
19. Brossart P, Stuhler G, Flad T, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998;58:732-6.
20. Seliger B, Rongcun Y, Atkins D, et al. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer 2000;87:349-59.
21. Bernhard H, Salazar L, Schiffman K, et al. Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer 2002;9:33-44.
22. Lustgarten J, Theobald M, Labadie C, et al. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD. 8. Hum Immunol 1997;52:109-18.
23. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-17.
24. Gilbertson RJ, Pearson AD, Perry RH, Jaros E, Kelly PJ. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995;71:473-7.
25. Schwechheimer K, Laufle RM, Schmahl W, et al. Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol 1994;25:772-80.
26. Hiesiger EM, Hayes RL, Pierz DM, Budzilovich GN. Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol 1993;16:93-104.
27. Chi DD, Merchant RE, Rand R, et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997;150:2143-52.
28. Scarcella DL, Chow CW, Gonzales MF, et al. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 1999;5:335-41.
29. Rimoldi D, Romero P, Carrel S. The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int J Cancer 1993;54:527-8.
30. Sahin U, Koslowski M, Tureci O, et al. Expression of cancer testis genes in human brain tumors. Clin Cancer Res 2000;6:3916-22.
31. Heim S. Cancer cytogenetics: chromosomal and molecular genetic aberrations of tumor cells, 2nd ed. New York: Wiley-Liss, Inc.; 1995.
32. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61:842-7.
33. Pellat-Deceunynck C, Mellerin MP, Labarriere N, et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol 2000;30:803-9.
34. Fonteneau JF, Larsson M, Somersan S, et al. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 2001;258:111-26.
35. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001;24:363-73.
36. De Smet C, De Backer O, Faraoni I, et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996;93:7149-53.
37. Weber J, Salgaller M, Samid D, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res 1994;54:1766-71.
38. Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003;63:8487-91.
39. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999;5:985-90.
40. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 2002;8:2851-5.
41. Liu G, Khong HT, Wheeler CJ, et al. Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother 2003;26:301-12.
42. Kruse CA, Cepeda L, Owens B, et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997;45:77-87.
43. Sotiriadou R, Perez SA, Gritzapis AD, et al. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 2001;85:1527-34.
44. Bonini C, Lee SP, Riddell SR, Greenberg PD. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 2001;166:5250-7.
45. Kobayashi H, Lu J, Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 2001;61:7577-84.
46. Lapointe R, Royal RE, Reeves ME, et al. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J Immunol 2001;167:4758-64.